Director Rowan E Chapman of Natera, Inc. (NASDAQ:NTRA) completed a sale of 122 common shares on March 13, 2026, at $191.38 per share, resulting in proceeds of $23,348. The trade was executed pursuant to a pre-established Rule 10b5-1 trading plan that Chapman adopted on December 12, 2025, and the transaction was reported on a Form 4 filing with the Securities and Exchange Commission.
Following the disposition, Chapman directly holds 5,752 shares of Natera. The Form 4 shows the sale was signed on Chapman’s behalf by Tami Chen, acting as Attorney-in-Fact.
Market movement since the sale has pushed Natera stock to $198.38, reflecting an approximately 36% return over the past year. Despite that year-long gain, the shares remain down about 13% year-to-date.
Company developments and clinical data
Natera also reported progress on its clinical and product fronts. The company published two peer-reviewed studies that evaluated its Signatera circulating tumor DNA (ctDNA) assay in patients with anal squamous cell carcinoma and those with locally advanced rectal cancer. According to the studies, patients who tested negative for Signatera at baseline or who cleared ctDNA during treatment experienced 100% one-year overall survival and 100% one-year progression-free survival.
In addition to the Signatera results, Natera launched a new whole genome sequencing test called Zenith genomics, developed in collaboration with MyOme. The test uses long-read sequencing technology to detect rare genetic conditions and complex genomic features, and Natera is presenting data on the test at a major genetics meeting.
Analyst activity
On the analyst front, Morgan Stanley adjusted its price target for Natera to $250 from $265 while maintaining an Overweight rating, citing updates to its financial models. Canaccord Genuity reiterated a Buy rating, pointing to fourth-quarter results that outperformed the company’s preannouncements.
Summary
Rowan E Chapman sold 122 Natera shares under a Rule 10b5-1 plan on March 13, 2026, producing $23,348 in proceeds; the sale was reported on a Form 4 and signed by an attorney-in-fact. Natera has recently published promising Signatera ctDNA data, introduced a long-read whole genome sequencing test named Zenith genomics with MyOme, and seen mixed analyst activity including a price-target adjustment by Morgan Stanley and a reiterated Buy from Canaccord Genuity. The stock sits at $198.38 following the trade, about 36% higher over one year but roughly 13% lower year-to-date.
Key points
- Insider transaction: Director Rowan E Chapman sold 122 shares on March 13, 2026, for $23,348 under a Rule 10b5-1 plan; Chapman now holds 5,752 shares.
- Clinical findings: Peer-reviewed studies of the Signatera ctDNA assay reported 100% one-year overall survival and progression-free survival for patients negative at baseline or who cleared ctDNA during treatment.
- Product launch and partnerships: Natera introduced Zenith genomics, a long-read whole genome sequencing test developed with MyOme, and is presenting related data at a major genetics meeting.
Risks and uncertainties
- Market volatility: Despite a one-year gain of about 36%, Natera shares are down around 13% year-to-date, indicating short-term price fluctuation risk for investors.
- Limited public detail: The summary of clinical outcomes is based on the reported peer-reviewed studies; the broader market and clinical community will weigh these findings as more data and presentations appear.
- Analyst adjustments: Changes in analyst models and price targets, such as Morgan Stanley’s reduction from $265 to $250, reflect financial-model sensitivity and could influence investor expectations.